Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12105119 | 0.84 | DAO (0.39) | TP53DAOFDPSLMNACA12 | |
| SCHEMBL27267348 | 0.80 | DAO (0.39) | TP53DAOFDPSLMNACA12 | |
| SCHEMBL12744440 | 0.79 | LMNA (0.36) | DAOFDPSLMNACA12CA1 | |
| SCHEMBL22792247 | 0.77 | BRD4 (0.38) | TP53DAOFDPSCA12CA1 | |
| SCHEMBL5713341 | 0.75 | DAO (0.50) | DAOFDPSLMNACA12CA1 | |
| SCHEMBL33257 | 0.73 | — | — | |
| SCHEMBL9466092 | 0.73 | KDM4E (0.52) | TP53LMNACA12CA1CA2 | |
| SCHEMBL27147600 | 0.72 | LMNA (0.39) | DAOFDPSLMNACA12CA1 | |
| SCHEMBL2845257 | 0.72 | — | — | |
| Bromide SCHEMBL556812 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332821-A1 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332821-A1 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | CD22, CD2, BCL6 | TP53 115/4885DAO 4253/4885FDPS 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.